UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Catalyst Event: PDUFA for **PYRUKYND® (mitapivat)** in thalassemia (label expansion) – **December 7, 2025**.
Technical Context (Daily/Weekly Chart): The stock experienced a **sharp decline** after mixed results in another study, breaking key supports. The price is **significantly below** the 200-day Moving Average (around $40.79), indicating a strong long-term bearish trend. The RSI is likely in or emerging from the **oversold** area, suggesting a potential technical bounce or that the primary selling pressure has subsided.
| Technical Level | Theoretical Price (USD) | Role |
|---|---|---|
| **Key Support** | $26.00 – $27.00 | Recent low/historical support level that could serve as a base for pre-PDUFA buying pressure. |
| **Immediate Resistance** | **$32.00 – $33.00** | Psychological and former support level that the price must overcome to reverse short-term sentiment. |
| **Bullish Target (Approval)** | **$40.00 – $42.00** | Corresponds to the **200-day Moving Average** and previous resistance/pre-fall high; a realistic target on a positive outcome. |
| **Bearish Target (Non-Approval)** | $20.00 – $22.00 | Subsequent historical low/support level in case of a strong sell-off. |
Catalyst Event: PDUFA for **ORLADEYO®** (berotralstat) in pediatric HAE (label expansion) – **December 12, 2025**.
Technical Context (Daily Chart): The stock is trading in a tight sideways range or a **mild short-term uptrend**, generally holding **near or above** key Moving Averages (50 and 200 days, with the 200-day MA around $7.064). Indicators like RSI and MACD are likely showing mild buy signals, suggesting increasing **accumulative pressure** ahead of the news. Analyst consensus remains strong (“Strong Buy”) with a 12-month average target significantly above the current price.
| Technical Level | Theoretical Price (USD) | Role |
|---|---|---|
| **Key Support** | $6.50 – $6.70 | Base of the recent trading range and strong support in case of pre-PDUFA profit-taking. |
| **Immediate Resistance** | $7.20 – $7.40 | Recent resistance level that, if broken, could trigger a move in anticipation of the event. |
| **Bullish Target (Approval)** | **$10.00 – $12.00** | Significant psychological level and previous historical peak/resistance. Breaking this opens the path to analyst targets. |
| **Bearish Target (Non-Approval)** | $5.00 – $5.50 | Significant historical support; a drop below the 200-day MA (around $7.06) would indicate a rapid move toward these lows. |
Catalyst Event: PDUFA for **CARDAMYST™** (etripamil) nasal spray (after CRL) – **December 13, 2025**.
Technical Context (Daily/Weekly Chart): The stock has shown **high volatility**, especially after a public offering caused a crash, followed by a strong recovery (52-week high indicated at $2.77). The price is in a **recovery trend** from historical lows, indicating buyers are dominating the short-term trend. Breaking the 52-week high resistance ($2.77) is crucial to confirm sustained bullish momentum (buy-in) before the event.
| Technical Level | Theoretical Price (USD) | Role |
|---|---|---|
| **Key Support** | $2.00 – $2.20 | Crucial psychological level that acted as a base during the recent recovery. |
| **Immediate Resistance** | **$2.75 – $3.00** | 52-week high and key psychological resistance. A break indicates strong pre-PDUFA momentum. |
| **Bullish Target (Approval)** | **$3.75 – $4.50** | Aligns with the **Average Analyst Price Target** ($3.75) and a previous trading zone before the crash. |
| **Bearish Target (Non-Approval)** | $1.00 – $1.50 | In case of a negative outcome (another CRL), the stock would likely fall back to or near historical lows with a potentially violent sell-off. |
Drug: PYRUKYND® (mitapivat)
Indication: Supplemental New Drug Application (sNDA) for treatment of adult patients with alpha- or beta-thalassemia (both transfusion-dependent and non-transfusion-dependent)
Mechanism: First-in-class oral pyruvate kinase (PK) activator
PDUFA Date: December 7, 2025 (extended from September 7, 2025)
Mitapivat is an oral, allosteric activator of the red blood cell pyruvate kinase enzyme. Phase 3 ENERGIZE and ENERGIZE-T trials demonstrated significant hemoglobin improvements and reduced transfusion burden in thalassemia patients.
FDA Extended PDUFA: On September 4, 2025, Agios announced the FDA extended the PDUFA goal date by three months (from September 7 to December 7, 2025) after the company submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) to address hepatocellular injury risk observed in clinical trials. [Globe Newswire, Sept 4, 2025]
At the 67th American Society of Hematology (ASH) Annual Meeting (December 6-9, 2025 in Orlando), Agios presented multiple abstracts highlighting mitapivat’s potential to:
[Source: Simply Wall St, Nov 24, 2025]
On November 20, 2025, Agios reported mixed topline results from its Phase 3 RISE UP trial evaluating mitapivat in sickle cell disease (SCD):
[Source: Investing.com, Nov 20, 2025]
| Firm | Rating | Price Target | Date |
|---|---|---|---|
| Leerink Partners | Outperform (Upgrade from Market Perform) | $34.00 | Nov 20, 2025 |
| Consensus (Multiple Analysts) | Moderate Buy | $25.00 – $48.00 range | Nov 2025 |
If approved, PYRUKYND would compete with luspatercept (Reblozyl, Bristol Myers Squibb) in the thalassemia market. Analysts note mitapivat’s oral administration (vs subcutaneous injection for luspatercept) as a potential differentiator, along with broader population eligibility.
Drug: ORLADEYO® (berotralstat) oral granules
Indication: Long-term prophylaxis of hereditary angioedema (HAE) attacks in pediatric patients aged 2 to under 12 years
Mechanism: Oral plasma kallikrein inhibitor
PDUFA Date: December 12, 2025 (extended from earlier 2025 date)
ORLADEYO is already approved and commercially available for HAE prophylaxis in adults and pediatric patients 12 years and older. The current PDUFA is for label expansion into younger pediatric patients (ages 2-11) using an oral granule formulation suitable for this age group.
APeX-P Trial (Phase 2): At the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (November 6-10, 2025 in Orlando), BioCryst presented a second interim analysis from the APeX-P trial showing:
[Source: Globe Newswire, Oct 23, 2025]
Q3 2025 Results (Reported Nov 3, 2025):
[Source: BioCryst Q3 2025 Earnings, Globe Newswire, Nov 3, 2025]
| Firm | Rating | Price Target | Date |
|---|---|---|---|
| Consensus (13 Analysts) | Moderate Buy | $19.18 | Nov 2025 |
| Price Target Range | – | $8.00 – $30.00 | Nov 2025 |
| JMP Securities | Market Outperform | $16.00 (raised from $15) | Aug 6, 2025 |
| Barclays | Hold | $7.00 (raised from $6) | Aug 6, 2025 |
[Sources: MarketBeat, CNN Business]
Pediatric HAE patients (ages 2-11) represent a significant underserved population. Current treatment options for this age group are limited, primarily consisting of on-demand therapies or injectable prophylaxis. ORLADEYO oral granules would be the first oral prophylactic option for this population.
Drug: CARDAMYST™ (etripamil) nasal spray
Indication: Treatment of paroxysmal supraventricular tachycardia (PSVT) – rapid heart rhythm condition
Mechanism: Novel, self-administered calcium channel blocker nasal spray
PDUFA Date: December 13, 2025
This is a resubmission following a Complete Response Letter (CRL). The FDA accepted Milestone’s response to the CRL on July 11, 2025, setting the new PDUFA target date of December 13, 2025.
Previous CRL (March 2025): The CRL cited chemistry, manufacturing, and controls (CMC) issues – notably, NO efficacy or safety concerns were raised. This is a critical distinction, as CMC-only CRLs typically have higher approval probability upon resubmission compared to efficacy/safety-related CRLs.
[Source: Globe Newswire, July 11, 2025]
At the American Heart Association (AHA) Scientific Sessions 2025 (November 10, 2025), Milestone presented new analysis of etripamil clinical data from >600 unique enrolled patients showing:
[Source: Milestone Q3 2025 Earnings, Globe Newswire, Nov 12, 2025]
CEO Joseph Oliveto stated: “We are approaching our December 13 PDUFA date with optimism and excitement. Our team has recently increased pre-launch activities to better enable market readiness. We strengthened our balance sheet, and together with the $75 million royalty payment upon FDA approval, we believe we have resources in place to drive a successful commercial launch.”
| Firm | Rating | Price Target | Date |
|---|---|---|---|
| Consensus (3 Analysts) | Strong Buy | $4.50 | Nov 2025 |
| Price Target Range | – | $4.00 – $5.00 | Nov 2025 |
| H.C. Wainwright | Buy (Reiterated) | $5.00 | Sept 17, 2025 |
[Sources: TipRanks, Stock Analysis]
PSVT affects an estimated 2-3 per 1,000 individuals in the U.S. Current standard of care involves emergency room visits and IV adenosine administration. Etripamil nasal spray would be the first self-administered treatment option, potentially avoiding ER visits and empowering patients to manage episodes at home.
Peak Sales Potential: Analysts project peak sales potential exceeding $700 million if approved, based on addressable U.S. PSVT population and pricing assumptions.
| Factor | AGIO (Dec 7) | BCRX (Dec 12) | MIST (Dec 13) |
|---|---|---|---|
| Event Type | sNDA (label expansion) | sNDA (pediatric expansion) | NDA (resubmission) |
| Approval Probability | Moderate (REMS requirement concern) | High (commercial drug + positive data) | Moderate-High (CMC-only CRL) |
| Revenue Status | Commercial (PYRUKYND for PKD) | Commercial ($590-600M FY25 guidance) | Pre-revenue |
| Market Cap (approx) | ~$450M | ~$1.5B | ~$200M |
| Analyst Consensus Target | $34 (Leerink) | $19.18 | $4.50 |
| Volatility Risk | High (binary PDUFA, small-cap) | Low-Moderate (existing revenue cushion) | High (pre-revenue, binary approval) |
| Recent Catalyst | ASH 2025 positive thalassemia data | ACAAI 2025 positive pediatric data | AHA 2025 consistent efficacy data |
All three PDUFA dates fall within a 7-day window (Dec 7-13, 2025). This creates potential for:
We use these professional tools for biotech research, catalyst tracking, and market analysis. Links below include affiliate partnerships that support our work.
Finviz Elite – Advanced stock screeners, real-time market data, pre-market scanners for small-cap biotech. Earn: 30% recurring commission on subscriptions.
Seeking Alpha Premium – Comprehensive biotech coverage, earnings transcripts, analyst ratings. Essential for PDUFA tracking and catalyst monitoring. Earn: Unlimited commissions.
ChartsWatcher – Professional stock scanner with pattern recognition and real-time alerts. Earn: 30% commission on up to 6 billing intervals.
Medved Trader – Lightning-fast charting & trading platform designed by traders for traders. Real-time alerts, Level 2 data, direct broker integration for PDUFA event preparation.
If you find value in our catalyst reports and biotech analysis, consider supporting our work:
Your support helps us continue delivering free, ad-free, unbiased biotech research. ?
Transparency: Affiliate links support our research. We only recommend services we personally use and trust.
Educational Purpose Only: This report is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendation, or an invitation to buy or sell securities.
No Guarantees: FDA decisions are binary regulatory events that can result in significant volatility. Each user is solely responsible for their own research and trading decisions.
Sources: All information compiled from publicly available sources including SEC filings, company press releases via Globe Newswire, analyst reports, and financial news outlets. While we strive for accuracy, errors or omissions may exist. Always verify information independently.
Regulatory Compliance: Not registered investment advice under SEC, CONSOB, or MiFID II regulations. For full disclaimers, visit merlintrader.com/disclaimer/
Related Merlintrader pages: This AGIO / BCRX / MIST December 2025 FDA catalyst article is historical. Verify every FDA outcome, label status, CRL, post-event filing and financing update before relying on the original setup. See Free FDA & PDUFA Calendar, Biotech Stocks Hub, PDUFA dates explained and join Telegram @merlintraderpub_com.
